Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ACADIA Pharmaceuticals ( (ACAD) ) has issued an update.
On April 30, 2026, Acadia Pharmaceuticals Inc. announced that Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, plans to retire at year-end for personal reasons, after joining the company in 2024. She will stay in her role until a successor is appointed and then continue as a consultant through at least the end of 2026 to help steer key milestones, including the Phase 2 readout of remlifanserin in Alzheimer’s disease psychosis and early Phase 3 execution.
Acadia has launched a search for a new Head of Research and Development and emphasized that its clinical portfolio, including Phase 2 studies of remlifanserin in Alzheimer’s disease psychosis and Lewy body dementia psychosis, continues as planned and remains blinded. The company framed the transition as managed and orderly, aiming to preserve scientific continuity and pipeline momentum while maintaining its strategic focus on neurological and rare disease programs important to patients and investors alike.
The most recent analyst rating on (ACAD) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.
Spark’s Take on ACAD Stock
According to Spark, TipRanks’ AI Analyst, ACAD is a Outperform.
The score is driven primarily by improved financial performance (profitability inflection and strong balance sheet) and constructive 2026 growth guidance from the earnings call, tempered by weak technical trend signals and cash-flow variability. Valuation is supportive with a modest P/E, while the corporate event is a minor positive.
To see Spark’s full report on ACAD stock, click here.
More about ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc., based in San Diego, is a biopharmaceutical company focused on developing and commercializing treatments for neurological and rare diseases. Its commercial portfolio includes the first and only FDA-approved therapies for Parkinson’s disease psychosis and Rett syndrome, and it is advancing a pipeline targeting Alzheimer’s disease psychosis, Lewy body dementia psychosis and other underserved conditions.
The company emphasizes a disciplined research and development strategy, with mid- to late-stage clinical programs such as remlifanserin for Alzheimer’s disease psychosis and Lewy body dementia psychosis, alongside earlier-stage assets. Acadia aims to address significant unmet medical needs globally, positioning itself as a specialist player in neuropsychiatric and rare disease markets.
On April 30, 2026, Acadia announced that Elizabeth H.Z. Thompson, Ph.D., its Head of Research and Development since 2024, plans to retire at year-end for personal reasons. She will remain in her current role until a successor is named and then serve as a consultant through at least the end of 2026 to support continuity around key milestones, including the Phase 2 readout of remlifanserin in Alzheimer’s disease psychosis and early Phase 3 execution.
The company has begun searching for a new R&D chief and stressed that its clinical programs, including Phase 2 studies of remlifanserin in Alzheimer’s disease psychosis and Lewy body dementia psychosis, are proceeding as planned and remain blinded. The transition underscores Acadia’s reliance on stable scientific leadership as it advances a curated pipeline, while reassuring investors and patients that operational and clinical development momentum will be maintained during the change in R&D leadership.
Average Trading Volume: 1,815,240
Technical Sentiment Signal: Buy
Current Market Cap: $3.84B
Find detailed analytics on ACAD stock on TipRanks’ Stock Analysis page.